20% Upside For Eli Lilly Stock?

Core Insights - Eli Lilly's stock has increased by 7% over the past month, driven by a partnership with Walmart to sell its weight-loss drug, Zepbound, at a discounted price [2] - The stock is currently trading within a support range of $772.85 to $854.21, which has historically attracted significant buying interest [3] - Following previous rebounds from this support range, Eli Lilly's stock has achieved an average peak return of 20.2% [3] Financial Performance - Eli Lilly reported a revenue growth of 36.8% for the last twelve months (LTM) and an average growth of 23.4% over the past three years [5] - The company has a free cash flow margin of approximately -0.09% and an operating margin of 43.0% LTM [5] - The lowest annual revenue growth in the last three years was 1.5% [5] - Eli Lilly's stock trades at a price-to-earnings (PE) ratio of 52.9 [5] Market Position - Compared to the S&P 500, Eli Lilly offers a higher valuation, increased revenue growth, and superior operating margins [5] - The stock has historically faced significant declines during market downturns, including a 51% drop during the Global Financial Crisis and a 43% drop during the Dot-Com bubble [6]